Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration

Pharmacotherapy

Volumn 34, Issue 9, 2014, Pages e162-e168

  Lopez, Natasha D ^a   Phillips, Kristy M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

critical care; CVVH; drug monitoring; fluconazole; hemofiltration; lean body weight; obesity; pharmacokinetics

Indexed keywords

FLUCONAZOLE; ANTIFUNGAL AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CONTINUOUS HEMOFILTRATION; CONTINUOUS INFUSION; CRITICAL ILLNESS; DOSE CALCULATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; LEAN BODY WEIGHT; MAINTENANCE DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MORBID OBESITY; DRUG MONITORING; HALF LIFE TIME; HEMOFILTRATION; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTIFUNGAL AGENTS; AREA UNDER CURVE; CRITICAL ILLNESS; DRUG MONITORING; FLUCONAZOLE; HALF-LIFE; HEMOFILTRATION; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OBESITY, MORBID;

EID: 84907984358     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1470     Document Type: Article

References (28)

1. Hanley MJ, Abernethy DR, Greenblatt DJ,. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71-87.
2. Schrier R, Wang W,. Acute renal failure and sepsis. N Engl J Med 2004; 351: 159-69.
3. Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J,. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009; 37: 2268-82.
4. Dodds Ashley E, Lewis R, Lewis JS, Martin C, Andes D,. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43: S28-39.
5. Andes D,. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 2003; 47: 1179-86.
6. Andes D,. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006; 20: 679-97.
7. Baddley JW, Patel M, Bhavnani SM, et al. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008; 52: 3022-8.
8. Pai MP, Turpin RS, Garey KW,. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2001; 51: 35-9.
9. Rodriguez-Tudela JL, Almirante B, Rodriguez-Pardo D, et al. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother 2007; 51: 3599-604.
10. Brammer KW, Farrow PR, Faulkner JK,. Pharmacokinetics and tissue penetration of fluconazole in humans. Clin Infect Dis 1990; 12 (Suppl 3): S318-26.
11. Bergner R, Hoffmann M, Riedel KD, et al. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. Nephrol Dial Transplant 2006; 21: 1019-23.
12. Muhl E, Martens T, Iven H, Rob P, Bruch HP,. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol 2000; 56: 671-8.
13. Valtonen M, Tiula E, Neuvonen PJ,. Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure. J Antimicrob Chemother 1997; 40: 695-700.
14. Scholz J, Schulz M, Steinfath M, Hover S, Bause H,. Fluconazole is removed by continuous venovenous hemofiltration in a liver transplant patient. J Mol Med 1995; 73: 145-7.
15. Cohen LG, DiBiasio A, Lisco SJ, et al. Fluconazole serum concentrations and pharmacokinetics in an obese patient. Pharmacotherapy 1997; 17: 1023-6.
16. Eschenauer GA, Carver PL,. The evolving role of antifungal susceptibility testing. Pharmacotherapy 2013; 33: 465-75.
17. Green B, Duffull SB,. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004; 58: 119-33.
18. Sinnollareddy M, Peake SL, Roberts MS, et al. Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. Int J Antimicrob Agents 2012; 39: 1-10.
19. Yagasaki K, Gando S, Matsuda N, et al. Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. Intensive Care Med 2003; 29: 1844-8.
20. Hope WW, Billaud EM, Lestner J, Denning DW,. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008; 21: 580-6.
21. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
22. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
23. Pai MP,. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis 2010; 17: e53-62.
24. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
25. Winter M,. Basic clinical pharmacokinetics. 5th ed. Baltimore, MD: Lippincott Williams &Wilkins, 2010.
26. Cheymol G,. Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet 2000; 39: 215-31.
27. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Informational supplement M27-A3. Wayne, PA: Clinical Laboratory Standards Institute Clinical Laboratory Standards Institute; 2008.
28. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Clin Infect Dis 1997; 24: 235-47.